CARA - キャラ・セラピュ―ティックス （Cara Therapeutics Inc.）

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment…

STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 24 th Annual Global Investment Conference on Tuesday, September 13, 2022, at 8:30 a.m. ET.

Korsuva has been approved in an indication for which it faces little in the way of competition. Click to read our analysis of Cara Therapeutics stock.

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st…

The Swiss Agency for Therapeutic Products (Swissmedic) approved Cara Therapeutics (CARA) and Vifor Fresenius Medical Care Renal Pharma''s Kapruvia…

Tudor Investment Corp Et Al bought a new stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 72,497 shares of the biopharmaceutical companys stock, valued at approximately $1,035,000. Tudor Investment Corp Et Al []

Cara Therapeutics Announces CEO Transition Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical

Cara Therapeutics (NASDAQ:CARA) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk. Institutional and Insider Ownership 62.0% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 56.8% []

Dimensional Fund Advisors LP lifted its stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 563.8% during the second quarter, Holdings Channel.com reports. The fund owned 420,671 shares of the biopharmaceutical companys stock after purchasing an additional 357,302 shares during the period. Dimensional Fund Advisors LPs holdings in Cara Therapeutics were worth $6,003,000 at the []

In the last trading session, 1.79 million shares of the Cara Therapeutics Inc. (NASDAQ:CARA) were traded, and its beta was 1.09. Most recently the companys share price was $16.83, and it changed around -$0.12 or -0.71% from the last close, which brings the market valuation of the company to $849.07M. CARA currently trades at a Cara Therapeutics Inc. (NASDAQ: CARA) Shares Are Heading Higher Read More »

GAINERS: Primo Nutraceuticals (OTC: BUGVF ) shares closed up 33.33% at $0.20 Inner Spirit Holdings (OTC: INSHF ) shares closed up 9.69% at $0.21 Greenlane Holdings (NASDAQ: GNLN ) shares closed up 8.44% at $6.04 EnWave (OTC: NWVCF ) shares closed up 7.44% at $1.30 RIV Capital (OTC: CNPOF ) shares closed up 6.67% at $1.92 Cara Therapeutics (NASDAQ: CARA ) … Full story available on Benzinga.com

STAMFORD, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and …

Stocks Analysis by Zacks Investment Research covering: Cara Therapeutic. Read Zacks Investment Research's latest article on Investing.com

Stocks that traded heavily or had substantial price changes Tuesday: Illumina, Cara Therapeutics rise; Greenbrier, Paychex fall

GAINERS: BioHarvest Sciences (OTC: CNVCF ) shares closed up 12.8% at $0.45 Emerald Health (OTC: EMHTF ) shares closed up 11.84% at $0.24 Cara Therapeutics (NASDAQ: CARA ) shares closed up 9.52% at $23.82 CV Sciences (OTC: CVSI ) shares closed up 6.52% at $0.49 The Flowr (OTC: FLWPF ) shares closed up 4.58% at $0.26 Australis Capital (OTC: AUSAF ) shares closed up 4.22% at $0.32 Zenabis Global (OTC: ZBISF ) shares closed up 3.99% at $0.10 Zelira Therapeutics (OTC: ZLDAF ) shares closed up 3.84% at $0.05 Neptune Wellness … Full story available on Benzinga.com